MiMedx Group, Inc.

NASDAQ:MDXG

Biotechnology

Healthcare
$3.18 +2.22%

+$0.08 today

Market cap
$464.04M
Beta
1.46
P/E (TTM)
17.8
EPS (TTM)
$0.21
52W Low $3.03High $7.99

Volume 1.51M

Average 1.55M

MDXG Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

MiMedx Group, Inc.NASDAQ: MDXG

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense turns negative

Q1 FY2026 income tax expense was -$4.47M, compared with $1.59M a year earlier. Trailing-twelve-month income tax expense was $11.62M. Over 3 fiscal years it compounded at +341.1% a year.

Context

  • Income tax expense amounted to 4.2% of revenue in FY2025, down 0.2 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near -$4.47M or moves back toward the trailing-twelve-month quarterly average of $2.91M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.47M-167.7% QoQ
Last fiscal yearDec 2025
$17.68M+15.6% YoY
LTMMar 2026
$11.62M-20.0% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-381.4%——
1 year+15.6%——
3-year CAGR+341.1%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
17.68M USD
Year-over-year change
+15.6%
4-year CAGR
+190.9%

Income Tax Expense vs competitors

How MDXG compares with its peers on the latest reported figures

  • MDXG's LTM Mar 2026 income tax expense of $11.62M is the highest of the 8 companies compared; the peer median is $0.
  • Its year-over-year change of -20.0% is the 4th highest of 5, against a peer median of +199.3%.
  • Income tax expense amounts to 3.0% of revenue for MDXG, versus a peer median of 0.5%.
MDXG Competitors Peer median
Income Tax Expense for MDXG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDXGMiMedx Group, Inc.LTM Mar 2026$11.62M -20.0%+341.1%3.0%
BSEMBioStem Technologies, Inc.LTM Jun 2026$4.65M +244.0%——
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$4.56M +154.6%+27.9%0.9%
MDWDMediWound Ltd.LTM Mar 2026$147K +250.0%+29.4%1.0%
SMTISanara MedTech Inc.LTM Mar 2026$0 ——0.0%
CELUCelularity Inc.LTM Dec 2025$0 —-38.7%0.0%
RCELAVITA Medical, Inc.LTM Mar 2026-$9K -128.1%-32.6%0.0%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026-$5.28M ——35.7%
Peer median (excluding MDXG) $0+199.3%-2.4%0.5%

Competitors are the stored peer set for MDXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue242.02M267.84M321.48M348.88M418.63M
Cost of Revenue39.63M48.32M54.63M60.07M73.01M
Gross Profit202.39M219.53M266.84M288.81M345.62M
Gross Margin83.6%82.0%83.0%82.8%82.6%
Research & Development9.93M12.7M12.67M12.34M15.1M
Selling, General & Admin194.85M220.85M216.3M216.39M266.19M
Operating Expenses209.44M234.25M229.73M229.94M281.29M
Depreciation & Amortization5.18M4.05M3.43M6.04M14.88M
EBITDA(1.89M)(10.69M)40.52M65.35M82.93M
EBITDA Margin-0.8%-4.0%12.6%18.7%19.8%
Operating Income(7.05M)(14.73M)37.12M58.87M63.89M
Operating Margin-2.9%-5.5%11.5%16.9%15.3%
Interest Income00004.72M
Interest Expense4.98M5.02M6.46M1.01M1.78M
Other Income / Expenses(5M)(5.02M)(6.48M)(1.57M)2.38M
Income Before Tax(12.05M)(19.75M)30.63M57.29M66.26M
Pre-Tax Margin-5.0%-7.4%9.5%16.4%15.8%
Income Tax Expense247K206K(36.81M)15.3M17.68M
Net Income(12.3M)(30.2M)67.44M42.42M48.58M
Net Margin-5.1%-11.3%21.0%12.2%11.6%
EPS (Basic)(0.09)(0.27)0.480.290.33
EPS (Diluted)(0.09)(0.27)0.380.280.32
Weighted Avg Shares110.35M112.91M116.5M146.98M147.79M
Weighted Avg Shares (Diluted)110.35M112.91M145.96M149.05M149.72M

MiMedx Group, Inc.

NASDAQ:MDXG

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.